PMDA — authorised 28 March 2016
- Marketing authorisation holder: Novartis Pharma K.K.
- Status: approved
PMDA authorised Tafinlar on 28 March 2016
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. PMDA authorised it on 28 March 2016.
Novartis Pharma K.K. holds the Japanese marketing authorisation.